<SEC-DOCUMENT>0000919574-24-003822.txt : 20240626
<SEC-HEADER>0000919574-24-003822.hdr.sgml : 20240626
<ACCEPTANCE-DATETIME>20240626200837
ACCESSION NUMBER:		0000919574-24-003822
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240618
FILED AS OF DATE:		20240626
DATE AS OF CHANGE:		20240626

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Casdin Amplify Fund, LP
		CENTRAL INDEX KEY:			0002028254
		ORGANIZATION NAME:           	
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34180
		FILM NUMBER:		241074992

	BUSINESS ADDRESS:	
		STREET 1:		1350 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 2600
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		212-300-5575

	MAIL ADDRESS:	
		STREET 1:		1350 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 2600
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STANDARD BIOTOOLS INC.
		CENTRAL INDEX KEY:			0001162194
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				770513190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2 TOWER PLACE
		STREET 2:		SUITE 2000
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6502666000

	MAIL ADDRESS:	
		STREET 1:		2 TOWER PLACE
		STREET 2:		SUITE 2000
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLUIDIGM CORP
		DATE OF NAME CHANGE:	20011113
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2024-06-18</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001162194</issuerCik>
        <issuerName>STANDARD BIOTOOLS INC.</issuerName>
        <issuerTradingSymbol>LAB</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002028254</rptOwnerCik>
            <rptOwnerName>Casdin Amplify Fund, LP</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>1350 AVENUE OF THE AMERICAS</rptOwnerStreet1>
            <rptOwnerStreet2>SUITE 2600</rptOwnerStreet2>
            <rptOwnerCity>NEW YORK</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>10019</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>545000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The securities are owned directly by Casdin Amplify Fund, LP (&quot;Amplify&quot;) and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Amplify (&quot;Casdin&quot;), (ii) Casdin Partners GP, LLC, the general partner of Amplify (the &quot;GP&quot;), and (iii) Eli Casdin, the managing member of Casdin and the GP.</footnote>
    </footnotes>

    <remarks>Eli Casdin has been deputized to represent the Reporting Person on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the &quot;Exchange Act&quot;), the Reporting Person may be deemed a director by deputization of the Issuer. The Reporting Person disclaims beneficial ownership in the securities reported on this Form 3 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.</remarks>

    <ownerSignature>
        <signatureName>Casdin Amplify Fund, LP, By: Casdin Partners GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member</signatureName>
        <signatureDate>2024-06-26</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
